Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07298928 for Effectiveness is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis 30 International Pediatric Open-Label
Clinical Trial NCT07298928 is an interventional study for Effectiveness and is currently not yet recruiting. Enrollment is planned to begin on March 10, 2026 and continue until the study accrues 30 participants. Led by The Children's Hospital of Zhejiang University School of Medicine, this study is expected to complete by December 1, 2028. The latest data from ClinicalTrials.gov was last updated on March 6, 2026.
Brief Summary
Under conventional treatment regimens, pediatric ocular myasthenia gravis (OMG) is prone to relapse and is associated with corticosteroid-related adverse effects, indicating an unmet clinical need. In May 2025, the targeted B-cell biologic agent Telitacicept was approved for use in adult patients with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (GMG) and subsequently initiated in nat...Show More
Official Title
The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health
Conditions
EffectivenessOther Study IDs
- KYYS-2025-0347
NCT ID Number
Start Date (Actual)
2026-03-10
Last Update Posted
2026-03-06
Completion Date (Estimated)
2028-12
Enrollment (Estimated)
30
Study Type
Interventional
PHASE
N/A
Status
Not yet recruiting
Keywords
long-term follow-up
Ocular myasthenia gravis
Telitacicept
Children
Biological agent
Targeted treatment
Ocular myasthenia gravis
Telitacicept
Children
Biological agent
Targeted treatment
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Experimentala single Telitacicept treatment group | Telitacicept All enrolled pediatric patients with OMG who meet the inclusion criteria will receive subcutaneous injections of Telitacicept on top of their existing medication regimen. The dose will be adjusted according to the patient's body weight: 160 mg per dose for those weighing ≥40 kg; 80 mg per dose for those weighing between 20 kg and \<40 kg; for patients weighing \<20 kg or aged \<5 years, a gradual dose reduction may b...Show More |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Ocular Myasthenia Gravis Rating Scale-q Score | This Ocular Myasthenia Gravis Rating Scale (OMGRate) is used to assess the impact of symptoms on the quality of daily life in patients with OMG. The OMGRate-q section of the scale is the patient - reported outcome component for evaluating the improvement of self - perceived symptoms. The questionnaire is completed based on the patient's condition over the past 2 weeks.
The total score ranges from 0 to 52 points, with higher scores indicating more severe symptoms and greater impairment of daily quality of life. | baseline, 1 week, 2 week,3 week,4 week,6 week, 8 week, 10 week,12 week, 16 week, 20 week, 24 week |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
quantitative Myasthenia Gravis scale | This scale is a standardized tool for the objective measurement of muscle strength and endurance in MG-affected muscle groups. It consists of 13 items covering the following aspects: eyes (onset time of diplopia and ptosis), facial muscles (lip closure strength), pharynx and larynx (swallowing and pronunciation tests), respiration (percentage of forced vital capacity relative to the predicted value), neck (duration of head lifting while lying supine), hand strength (strength reduction measured by a dynamometer), and limbs (duration of posture maintenance).
Each item is scored on a 4-point scale: 0 (normal), 1 (mild), 2 (moderate), and 3 (severe), with a total score ranging from 0 to 39. Higher scores indicate more severe symptoms. | baseline, 1 week, 2 week,3 week,4 week,6 week, 8 week, 10 week,12 week, 16 week, 20 week, 24 week |
Myasthenia Gravis⁃activity of daily living scale | This scale is mainly used to assess the impact of symptoms on the quality of daily life in patients with MG and reflect the severity of the disease.
It includes 8 items covering 4 aspects: eyes (frequency of ptosis and diplopia), bulbar region (degree of involvement in speech, chewing, and swallowing), respiration (relationship between breathing and physical activity), and limbs (ability to complete daily movements).
Each item is scored on a scale of 0 (normal) to 3 (most severe), with a total score ranging from 0 to 24. Higher scores indicate greater disease severity. | baseline, 1 week, 2 week,3 week,4 week,6 week, 8 week, 10 week,12 week, 16 week, 20 week, 24 week |
Number and proportion of children patients who have their hormone therapy discontinued | 8 week, 16 week, 24 week | |
The incidence and severity of adverse events | baseline, 4 week, 8 week, 12 week, 24 week |
Participation Assistant
Eligibility Criteria
Eligible Ages
Child, Adult
Eligible Sexes
All
The patient and their legal guardian voluntarily sign the informed consent form.
Age < 18 years, male or female.
Diagnosis of OMG according to the Chinese Guidelines for the Diagnosis and Treatment of Myasthenia Gravis (2025 Edition).
Stable administration of any one or combination of the following standard treatments prior to enrollment:
- Cholinesterase inhibitors
- Glucocorticoids
- Active infection under treatment： Patients who are HBsAg positive must be excluded. Patients who are HBsAg negative but HBcAb positive must undergo quantitative HBV-DNA testing. Patients with a positive quantitative HBV-DNA result must be excluded; those with a negative result may be enrolled.
- Severe hepatic or renal insufficiency.
- Patients with malignant tumors other than thymoma.
- Patients within 3 months post-thymectomy.
- Hypogammaglobulinemia (IgG < 400 mg/dL) or IgA deficiency (IgA < 10 mg/dL).
- History of allergy to human-derived biological products.
- Participation in any other clinical trial within 28 days prior to enrollment or within 5 times the half-life of the investigational drug from the previous trial (whichever is longer).
- Patients deemed unsuitable for participation by the investigator (e.g., patients with severe psychiatric disorders).
The Children's Hospital of Zhejiang University School of MedicineStudy Responsible Party
Shanshan Mao, Principal Investigator, Directo, The Children's Hospital of Zhejiang University School of Medicine
Study Central Contact
Contact: Shanshan Mao, 15990042668, [email protected]
3 Study Locations in 1 Countries
Guangdong
Shenzhen children's Hospital of China Medical University, Shenzhen, Guangdong, China
Xufeng Luo, Contact, 19012770239, [email protected]
Shandong
Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China
Kai Ma, Contact, 18358628830, [email protected]
Zhejiang
The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310052, China
Shanshan Mao, Contact, 15990042668, [email protected]